Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 807-157-1 | CAS number: 129677-93-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Oral: OECD 422, rat, NOAEL fertility ≥ 1000 mg/kg bw/day (read-across)
Oral: OECD 422, rat , NOAEL systemic ≥ 1000 mg/kg bw/day (read-across)
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06 Jun - 04 Aug 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted in 22 Mar 1996
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD(SD)BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Italia S.p.A., Calco (Lecco), Italy
- Age at study initiation: 6 to 7 weeks
- Weight at study initiation: 191 to 204 g (males) and 172 to 179 g (females)
- Housing: From arrival to pairing: animals were housed 5 of one sex to a cage, in polysulphone solid bottomed cages measuring 59.5x38x20 cm (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Nesting material was provided inside suitable bedding bags and changed at least twice a week.
During mating: animals were housed one male to one female in clear polysulphone cages measuring approximately 43x27x18 cm with a stainless steel mesh lid and floor (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Each cage tray held absorbent material which was inspected and changed daily. After mating, the males were re-caged as they were before mating; the females were transferred to individual solid bottomed cages (Techniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy) for the gestation period and parturition.
- Diet: laboratory rodent diet, 4 RF 21 (Mucedola S.r.l., Settimo Milanese (MI), Italy), ad libitum
- Water: drinking water, ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous carboxymethylcellulose (0.5% CMC)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The test substance was suspended in the vehicle. Formulations were prepared daily.
VEHICLE
- Concentration in vehicle: 10, 30 and 100 mg/mL for dose levels of 100, 300 and 1000 mg/kg bw/day, respectively
- Amount of vehicle: 10 mL/kg bw - Details on mating procedure:
- - M/F ratio per cage: 1 male to 1 female (monogamous).
- Length of cohabitation: The female was placed with the same male until pregnancy had occurred or 2 weeks had elapsed.
- Proof of pregnancy: Vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy.
- After 2 weeks of unsuccessful pairing replacement of first male by another male with proven fertility.
- After successful mating each pregnant female was caged singly. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability of the test substance in the vehicle were verified by gas chromatopgraphy with a flame ionisation detection (FID). Concentration verification was conducted on a weekly basis.
- Duration of treatment / exposure:
- Males: The daily administration of the test item was started two weeks before mating and lasted until test day 28 to 29, which was one day before sacrifice.
Females: The daily administration of the test item was started two weeks before mating and continued until day 3 post-partum.
Maximum: 54 days of treatment. - Frequency of treatment:
- once daily; 7 days/week
- Details on study schedule:
- not applicable for OECD 422 study
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on a 14-day range-finding study (Rossiello, 2013. RTC Study No.: 93730EXT)
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily during the study, each animal was observed and any clinical signs recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once before commencement of treatment and at least once a week thereafter, each animal was given a detailed clinical examination. Each animal was removed from the home cage and observed in an open arena. The tests included observation of changes in gait and posture, reactivity to handling, presence of clonic or tonic movements, stereotypes or bizarre behaviour and effects on the autonomic nervous system (e.g. lachrymation, piloerection, pupil size, unusual respiratory pattern).
BODY WEIGHT: Yes
- Time schedule for examinations: females: weekly from allocation to positive identification of mating and on gestation Days 0, 7, 14 and 20. Dams were also weighed on Days 1 and 4 post partum.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: The weight of food consumed by each cage of males and females was recorded weekly during the pre-mating period starting from allocation. Individual food consumption for the females was measured on gestation Days 7, 14 and 20 starting from Day 0 post coitum and on Day 4 post partum starting from Day 1 post partum.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
For further observations and examinations (water intake, haematology, clinical chemistry, neurobehaviour), see "Repeated dose toxicity: oral" (chapter 7.5.1)
OTHER:
Reproduction paramters: number of pregnant females, pre-coital time, gestation length - Oestrous cyclicity (parental animals):
- Vaginal smears were taken daily in the morning starting two weeks before pairing until a positive identification of copulation was made. The vaginal smear data were examined to determine the following: anomalies of the oestrous cycle and pre-coital interval (i.e., the number of nights paired prior to the detection of mating).
- Sperm parameters (parental animals):
- Parameters examined in P male parental generations:
testis weight, epididymis weight, and qualitative sperm staging.
In addition, the testes and epididymides were cut at 2-3 micrometer thickness and stained with Periodic Acid Schiff (PAS). The morphological evaluation of the seminiferous epithelium (staging of spermatogenic cycle) was performed. A detailed qualitative evaluation of testes was performed on 5 randomly selected control and high dose males. The evaluation took into account the tubular stages of the spermatogenic cycle, in order to identify treatment-related effects such as: missing germ cell layers or types, retained spermatids, multinucleated or apoptotic germ cells and sloughing of spermatogenic cells into the lumen. - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: litter weight, number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies
GROSS EXAMINATION OF DEAD PUPS:
Yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals [males were sacrificed on day 29 or 30]
- Maternal animals: All surviving animals [females were sacrifices on day 4 post-partum or shorty thereafter]
GROSS PATHOLOGY: Yes
-Organ weights: adrenal glands, brain (cerebrum, cerebellum, medulla/pons), epididymides, heart, kidneys, liver, ovaries with oviducts, parathyroid glands, prostate gland, seminal vesicles with coagulating glands, spleen, testes, thymus (where present), thyroid and uterus-cervix,
-Fixation: adrenal glands, bone marrow (from sternum), brain (cerebrum, cerebellum, medulla/pons), caecum, clitoral gland, colon, duodenum, epididymides, heart, ileum (including Peyer’s patches), jejunum, kidneys, liver, lungs (including mainstem bronchi), lymph nodes (mesenteric and cervical), ovaries with oviducts, parathyroid glands, pituitary gland, penis, preputial gland, prostate gland, rectum, sciatic nerve, seminal vesicles with coagulating glands, spinal column, spinal cord (cervical, thoracic, lumber), spleen, stomach, testes, thymus (where present), thyroid, trachea, urinary bladder, uterus-cervix and vagina.
HISTOPATHOLOGY: Yes, all organs that were included for fixation (5/sex of control and high dose group) - Postmortem examinations (offspring):
- SACRIFICE
- The surviving F1 offspring were sacrificed at 4 days of age.
GROSS NECROPSY
- Gross necropsy consisted of [external and internal examinations].
Dead pups and pups sacrificed at day 4 post-partum, or shortly thereafter, were carefully examined externally for gross abnormalities.
HISTOPATHOLOGY / ORGAN WEIGTHS
not performed - Statistics:
- Standard deviations were calculated as appropriate. For continuous variables the significance of the differences amongst group means was assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data. The non-parametric Kruskal-Wallis analysis of variance was used for the other parameters. Intergroup differences between the control and treated groups were assessed by the nonparametric version of the Williams test.
The criterion for statistical significance was p<0.05 - Reproductive indices:
- Male Copulatory Index (%) = No. of animals mated/No. of animals paired x 100
Male Fertility Index (%) = No. of males which induced pregnancy/ No. of males paired x 100
Female Copulatory Index (%) = No. of animals mated/No. of animals paired x 100
Female Fertility Index (%) = No. of pregnant females/No. of females paired x 100
Males and females:
Precoital interval = Mean number of days between pairing and mating - Offspring viability indices:
- Pre-implantation loss [%] = (No. of corpora lutea - No. of implantations/ No. of corpora lutea) x 100
Pre-birth loss [%] = (No. of visible implantations - total litter size at birth/ No. of visible implantations
) x 100
Pup loss at birth [%] = (Total litter size - live litter size/ Total litter size) x 100
Cumulative pup loss on Day 4 post-partum [%] = (Total litter size at birth - live litter size at Day 4/ Total litter size at birth) x 100 - Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects obseved in the study
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed in the study
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- All pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two control females had unilateral implantation but was not treatment related.
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed in the study
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- The source substance Tetradecyl-Oleate (CAS 22393-85-7) was tested in a combined repeated dose toxicity and reproduction/developmental toxicity screening study. A NOAEL of ≥ 1000 mg/kg bw/day for parental systemic toxicity and also for parental fertility was derived for male and female rats under the described test conditions.
Reference
No relevant clinical signs or mortality were observed in males and females throughout the study.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
No difference of toxicological significance were seen in body weight or body weight gain. No intergroup differences were seen in food consumption.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
No relevant difference in oestrous cycle was observed in treated females when compared to controls.
REPRODUCTIVE FUNCTION: SPERM MEASURES (PARENTAL ANIMALS)
Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and to the integrity of the various cell types within the different stages; regular layering in the germinal epithelium was noted.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
The number of corpora lutea, implantations, total litter size, pre-implantation loss and pre-birth loss did not differ significantly between groups. Gestation length was also comparable between groups. No differences were observed in the pre-coital interval, copulatory and fertility indices between control and treated groups.
ORGAN WEIGHTS (PARENTAL ANIMALS)
No relevant differences in terminal body weight or organ weights were seen between the controls and treated animals of both sexes
GROSS PATHOLOGY (PARENTAL ANIMALS)
No remarkable changes were noted at post mortem examination in treated animals when compared with controls.
HISTOPATHOLOGY (PARENTAL ANIMALS)
No treatment-related changes were observed. The lesions reported in control and treated animals were considered to be an expression of spontaneous and/or incidental pathology, commonly seen in this species and age under the experimental conditions.
All pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two control females had unilateral implantation. This finding was considered incidental since it was observed also in two control females.
CLINICAL SIGNS (OFFSPRING)
Clinical signs of pups such as pallor, cold to touch, small and/or bruise muzzle, were observed in control, mid- and high dose groups. No toxicological relevance was attributed to these signs since they were seen in treated as well as in control groups.
BODY WEIGHT (OFFSPRING)
Litter data including mean litter and pup weights were comparable between groups. Sex ratio of pups showed a slight increased number of males in high dose group respect to control. No toxicological relevance was attribute to the statistical significant increase observed on Day 4.
GROSS PATHOLOGY (OFFSPRING)
Decedent pups were generally autolysed. No signs were seen in pups sacrificed on Day 4 post partum.
Table 1: Fate of females: Group incidence
|
Treatment (mg/kg/bw/d) |
|||
0 |
100 |
300 |
1000 |
|
Initial group site |
10 |
10 |
10 |
10 |
Unilateral Implantation |
2 |
0 |
0 |
1 |
Total litter loss |
0 |
0 |
0 |
1 |
With live pups on day 4 post-partum |
10 |
10 |
10 |
9 |
Table 2: Implantation, pre-implantation loss data, pre-birth loss data and gestation length of females – Group mean data
Treatment (mg/kg/bw/d) |
|
Corpora Lutea |
Implantations |
Total Litter size at birth |
Pre-implantation loss % |
Pre-birth loss % |
Gestation length (days) |
|
0 |
Mean |
18.40 |
18.10 |
15.60 |
1.44 |
12.70 |
22.10 |
|
SD |
3.37 |
3.18 |
5.27 |
3.17 |
25.82 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
100 |
Mean |
16.30 |
15.80 |
14.20 |
3.26 |
10.09 |
22.10 |
|
SD |
3.23 |
3.61 |
3.49 |
8.44 |
8.48 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
300 |
Mean |
16.90 |
16.90 |
15.60 |
0.00 |
7.65 |
22.0 |
|
SD |
1.97 |
1.97 |
2.17 |
0.00 |
7.35 |
0.00 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
1000 |
Mean |
18.10 |
17.40 |
16.40 |
6.16 |
8.21 |
22.10 |
|
SD |
5.17 |
5.32 |
5.44 |
12.73 |
9.93 |
0.32 |
|
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
Table 3: Litter data at birth, on day 1 and on day 4 post-partum of pregnant females – Group mean data
Treatment (mg/kg/bw/d) |
|
At birth |
On day 1 post-partum |
On day 4 post-partum |
||||||
Total litter size |
Live litter size |
Pup loss (%) |
Litter weight (g) |
Mean pup weight (g) |
Live litter size |
Cumulative loss (%) |
Litter weight (g) |
Mean pup weight (g) |
||
0 |
Mean |
15.60 |
15.40 |
1.13 |
101.62 |
7.00 |
14.40 |
6.37 |
132.38 |
9.61 |
SD |
5.27 |
5.19 |
2.40 |
30.0 |
1.09 |
4.60 |
7.58 |
36.25 |
1.58 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
100 |
Mean |
14.20 |
14.20 |
0.00 |
96.87 |
7.01 |
14.10 |
0.56 |
145.70 |
10.51 |
SD |
3.49 |
3.49 |
0.00 |
19.08 |
0.81 |
3.38 |
1.77 |
29.27 |
1.08 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
300 |
Mean |
15.60 |
15.60 |
0.00 |
106.70 |
6.94 |
14.80 |
5.51 |
143.13 |
9.76 |
SD |
2.17 |
2.17 |
0.00 |
13.11 |
0.44 |
2.66 |
5.60 |
22.54 |
0.97 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
1000 |
Mean |
16.40 |
16.20 |
5.50 |
115.50 |
7.10 |
15.60 |
13.30 |
163.63 |
9.46 |
SD |
5.44 |
5.67 |
15.71 |
41.59 |
0.55 |
5.82 |
30.67 |
22.38 |
0.74 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
9 |
9 |
Table 4: Sex ratio of pups – Group mean data
Treatment (mg/kg/bw/d) |
|
At birth |
On day 4 post-partum |
||||||
Males |
Females |
Total |
% Males |
Males |
Females |
Total |
% Males |
||
0 |
Mean |
6.90 |
8.70 |
15.60 |
49.67 |
6.40 |
8.00 |
14.40 |
49.66 |
SD |
2.02 |
4.03 |
5.27 |
19.96 |
1.71 |
3.59 |
4.60 |
19.93 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
100 |
Mean |
6.90 |
7.30 |
14.20 |
50.50 |
6.80 |
7.30 |
14.10 |
50.14 |
SD |
1.79 |
2.95 |
3.49 |
15.38 |
1.81 |
2.95 |
3.38 |
15.72 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
300 |
Mean |
6.20 |
9.40 |
15.60 |
39.23 |
5.90 |
8.90 |
14.80 |
39.36 |
SD |
2.20 |
1.65 |
2.17 |
11.28 |
2.08 |
1.66 |
2.66 |
10.29 |
|
n |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
1000 |
Mean |
9.10 |
7.30 |
16.40 |
55.58 |
9.56* |
7.78 |
17.33 |
55.66 |
SD |
3.57 |
3.62 |
5.44 |
12.47 |
2.24 |
2.86 |
2.06 |
12.97 |
|
n |
10 |
10 |
10 |
10 |
9 |
9 |
9 |
9 |
*= mean value of group is significantly different from control
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 2 due to read-across) from a reference substance with similar structure and intrinsic properties. Read-across is justified based on common precursors and breakdown products of hydrolysis and consistent trends in environmental fate, ecotoxicological and toxicological profile (refer to the endpoint discussion for further details). The available data is thus sufficient to fulfil the standard information requirements set out in Annex VIII-IX, 8.7, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for read-across
There are no data on the reproduction toxicity of Fatty acids C8-10, C8-10 alkyl esters (CAS 129677-93-6). The assessment was therefore based on studies conducted with analogue substances as part of a read-across approach, which is in accordance with Regulation (EC) No. 1907/2006, Annex XI, 1.5. For each specific endpoint the source substance(s) structurally closest to the target substance is/are chosen for read-across, with due regard to the requirements of adequacy and reliability of the available data. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the grouping of chemicals and read-across is provided in the technical dossier (see IUCLID Section 13) and within Chapter 5.1 of the CSR.
Toxicity to reproduction
CAS 22393-85-7
A combined repeated dose toxicity and reproduction/developmental toxicity screening study was performed according to OECD Guideline 422 under GLP conditions (Key, 2014). 10 rats/sex/dose were administered 0, 100, 300 and 1000 mg/kg bw/day Tetradecyl oleate (CAS 22393-85-7) once daily, via gavage. Males were exposed for 28 - 29 days, from two weeks before mating on test day one until after mating. Females were exposed for 54 days (during 2 weeks prior to mating, during mating, during post-coitum, and during 3 days of lactation).
No treatment-related parental effects were seen on viability, clinical signs, body weight (gain), food consumption, haematological parameters, clinical chemistry parameters, during observational and neurological screening, and during macroscopic and microscopic examinations. Therefore the NOAEL for parental systemic toxicity was ≥ 1000 mg/kg bw/day.
In parental animals, no effects on reproductive function (qualitative sperm staging, oestrus cycle) or performance (male and female mating and fertility indices, conception index, precoital interval, and number of corpora lutea and implantation sites, gestation length) were observed, compared with the control animals. The testis weight, epididymis weight, and histological examination of the testes in males as well as the weight and histological examination of the uterus and ovaries in females did not reveal any substance-related effects in the parental animals. All the pregnant females gave birth to live pups with the exception of one high dose female which had a total litter loss on day 3 post-partum. This female and two females in the control group had unilateral implantation, which is not considered to be treatment-related. Therefore, a NOAEL for parental fertility of ≥ 1000 mg/kg bw/day was derived for male and female rats.
Overall conclusion for effects on fertility
There are no available studies on the toxicity to reproduction and fertility of Fatty acids C8-10, C8-10 alkyl esters. Therefore analogue read-across from a source substance was applied.
The potential for reproductive toxicity of the source substance (Tetradecyl oleate, CAS 22393-85-7) was assessed in a reproductive/developmental screening study (OECD 422). The NOAEL value for fertility was at the currently applied limit dose value of 1000 mg/kg bw/day. Therefore, no hazard to reproduction was identified. Based on the available data and following the analogue approach, the target substance Fatty acids C8-10, C8-10 alkyl estersis considered to not affect fertility.
Regulation (EC) No. 1907/2006, Annex IX, 8.7.3 Column 1, states that an extended one-generation reproduction toxicity study (OECD 443, basic test design or with additional modules) is required in one species, using the most appropriate route of administration, and having regard to the likely route of human exposure, ‘if the available repeated dose toxicity studies (e.g. 28-day or 90-day studies. OECD 421 or 422 screening studies) indicate adverse effects on reproductive organs or tissues or reveal other concerns in relation with reproductive toxicity’.
Therefore, in accordance with Annex IX, 8.7.3, Column 1, the registrant has considered the need to perform an extended one-generation reproduction toxicity study. In conclusion, information is available from the physico-chemical characteristics of the source and target substances and from studies performed with source substances of varying chain length and branching patterns, under different guidelines connected to reproduction and fertility. It is reasonable to assume for the source substance Fatty acids C8-10, C8-10 alkyl esters (CAS 129677-93-6), that the lack of reproductive effects noted in the available studies will reflect the results of reproductive parameters assessed specifically in an extended one-generation reproduction toxicity study. Therefore, referring to Regulation (EC) No. 1907/2006, Annex IX, 8.7.3, Column 1, performing an extended one-generation reproduction toxicity study (basic test design or with additional modules) is not scientifically necessary and, considering concerns regarding the use of vertebrate animals for experimental purposes, unjustified (please see further details in the IUCLID Section 7.8.1 'data waiving').
Effects on developmental toxicity
Description of key information
Oral: OECD 414, rat, NOAEL development ≥ 1000 mg/kg bw/day (read-across)
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 28 Jun - 21 Jul 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- Short treatment period (Day 6-15 of gestation), body weight was recorded on Day 0, 6, 16 and 20 only, food consumption was not recorded, the analytical purity of the test substance was not specified.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- exposure from Day 6 to Day 15 of gestation, body weight was recorded on Day 0, 6, 16 and 20, food consumption was not recorded
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Sprague-Dawley, CD
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Wiga GmbH, Sulzfeld, Germany
- Age at study initiation: 8 weeks
- Weight at study initiation: 202.6 ± 20.4 g - 219 ± 25.6 g (range of group mean values)
- Housing: the animals were housed individually in Makrolon Type M3 cages (Ebeco, Castrop-Rauxel, Germany), on standard softwood bedding (ARWI-Center, Essen, Germany)
- Diet: pelleted Altromin Maintenance Diet 1324 (Fa. Altromin GmbH, Lage, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-24
- Humidity (%): 48-82
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12 (lux units 50 - 550)
IN-LIFE DATES: From: 28 Jun 1994 To: 21 Jul 1994 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% sodium carboxymethylcellulose + 0.25% Cremophor in aqua dest.
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was prepared daily before administration, adjusted to the body weight measured on Day 6 of gestation.
VEHICLE
- Concentration in vehicle: 1, 3, 10% (10, 30, 100 mg/mL)
- Amount of vehicle (if gavage): 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The mixture of the test item was analysed once to verify the actual concentration. The measured concentration was within the expected range. The nominal concentrations 1 % (100 mg/kg bw/day), 3 % (300 mg/kg bw/day) and 10 % (1000 mg/kg bw/day) were measured to be 1.1%, 3.0% and 10.5%, respectively.
- Details on mating procedure:
- - Any other deviations from standard protocol: Primiparous time-mated females were used. The females were mated at the supplier with an accurate day of mating and received at the testing facility on gestation day 0.
- Duration of treatment / exposure:
- Day 6-15 of gestation
- Frequency of treatment:
- daily, 7 days/week
- Duration of test:
- 10 days; Day 6-15 of gestation
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 23 P females (100 and 300 mg/kg bw/day)
24 P females (control, 1000 mg/kg bw/day) - Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: on Day 0 (prior to administration), 6, 16 and 20 of gestation
FOOD CONSUMPTION: No
WATER CONSUMPTION: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: gross macroscopic examination of all reproductive and gender-specific organs, with emphasis on the uterus, uterine contents, position of the fetuses in the uterus and number of corpora lutea - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: weight of fetuses - Fetal examinations:
- - External examinations: Yes, all fetuses
- Soft tissue examinations: Yes, half per litter (146 fetuses of group 1, 133 fetuses in group 2, 169 fetuses in group 3 and 162 fetuses in group 4)
- Skeletal examinations: Yes, half per litter (159 fetuses of group 1, 144 fetuses in group 2, 178 fetuses in group 3 and 172 fetuses in group 4)
- Head examinations: No
Group 1: control
Group 2: 100 mg/kg bw/day
Group 3: 300 mg/kg bw/day
Group 4: 1000 mg/kg bw/day - Statistics:
- If the variables could be assumed to follow a normal distribution, the Dunnett-Test, based on pooled variance, was applied for comparion between groups. The Steel-Test was applied when the data could not be assumed to follow a normal distribution. Fisher's Exact test for 2x2 tables was applied if the variables could be dichotomized without loss of information (Bonferroni-Holm-corrected).
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
There was no mortality during the study period. No signs of systemic toxicity were observed. The mean body weight of the mid-dose group was statistically significantly increased on Day 16 and 20 of the study period (see Table 1). This considered to be an incidental observation, as the body weight gain over the study period was comparable between the control and treatment groups (58.9, 67.8, 57.4 and 59.6 g for the control, 100, 300 and 1000 mg/kg bw/day group, respectively). One female in each of the control group and the low-dose group was not pregnant, while all the pregnant females had viable fetuses (see Table 2).
No substance-related effects on the reproductive parameters (number of corpora lutea, implantation sites, pre-implantation loss, post-implantation loss, embryonic deaths, embryonic resorptions, fetal resorptions, live fetuses, dead fetuses) were observed (see Table 3). The necropsy and macroscopic examination did not show any treatment-related effects. One female in the high-dose group had blood in the uterine horn, but this is not considered to be treatment-related as no other effects were observed. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
The external examination of the foetuses did not reveal any treatment-related macroscopical effects. The skeletal examination showed a statistically significant increase in the number of foetuses with 6 ossified sternebrae in the high-dose group (see Table 5). As there were no increases in ossification anywhere else and no overall increase in abnormal findings for this group, the result is considered to be incidental. The results for the remaining offspring parameters (body weight, placental weight, sex ratio) were comparable between the control and treatment groups. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: teratogenicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: embryotoxicity
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- The test substance had no effect on intrauterine development.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- exposure duration was only from day 6-15 of gestation instead of day 5-19
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 2001
- Deviations:
- yes
- Remarks:
- Exposure duration was only from day 6-15 of gestation instead of day 5-19.
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga, Sulzfeld, Germany
- Age at study initiation: approx. 8-10 weeks
- Weight at study initiation: mean approx. 197 g
- Housing: individually in Makrolon Type M3 cages (Ebeco) with standard softwood bedding (ARWI-Center, Essen, Germany)
- Diet: Pelleted Altromin Maintenance Diet 1324, Lot No. 221092/1558 (Altromin GmbH, Lage, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-23
- Humidity (%): 40-56
- Air changes (per hr): 10-15 per hr
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: Arachidis oil, DAB 10
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The dosing solutions were prepared daily before administration.
VEHICLE
- Justification for use and choice of vehicle (if other than water): solubility of test substance
- Concentration in vehicle: 20, 60 and 200 mg/mL, respectively for the 100, 300 and 1000 mg/kg bw dose groups
- Amount of vehicle (if gavage): 5 mL/kg bw
After arrival all females were assigned to the different groups using a computer-generated random algorithm. - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant, at day 0
- Proof of pregnancy: vaginal plug day 0 of pregnancy - Duration of treatment / exposure:
- from day 6 up to day 15 of gestation
- Frequency of treatment:
- once daily
- Duration of test:
- until day 20 of gestation
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Other:
group 1: 0 mg/kg bw/day
group 2: 100 mg/kg bw/day
group 3: 300 mg/kg bw/day
group 4: 1000 mg/kg bw/day - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
Mortality rate: The animals were checked at least twice daily for any mortality.
Signs and/or symptoms: The animals were observed at least twice daily (working days) for signs of reaction to treatment and/or symptoms of illness.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Post mortem examination, including gross macroscopic examination of all maternal organs, with emphasis on the uterus, uterine contents, position of fetuses in the uterus and number of corpora lutea, was performed and the data recorded.
The uteri (including content) of all females were weighed at necropsy on day 20 post coitum to enable the calculation of the corrected body weight gain.
- Any female sacrificed or found dead during the study was subjected to macroscopic examination of the visceral organs, with emphasis on the uterus and its content.
BODY WEIGHT: Yes, mean body weight changes
- Time schedule for examinations: days 0, 6, 16 and 20 of gestation - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Number and distribution of intrauterine implantations were classified as live or death fetuses, late intrauterine deaths (resorptions), early intrauterine (resorption sites). The fetuses were removed from the uterus. Intrauterine deaths were classified on the basis of the presence (late) or absence (early) of fetal or decidual tissue in addition to placental tissue. - Fetal examinations:
- - External examinations: Yes: half per litter
- Soft tissue examinations: Yes: half per litter: malformations oh hydrocephalus, variations of brain, adrenal gland, renal pelvis, ureter
- Skeletal examinations: Yes: half per litter: malformations of hydrops, retardations of skull bones, hyoid, sternebrae, pelvis, 13th rib
- Head examinations: Yes: half per litter
The live fetuses were sexed, weighed individually including placentae, examined for gross external abnormalities and allocated to one of the following procedures:
1) Half of the fetuses from each litter was non individually fixed in Bouin's solution in order to examine viscera and brain by Wilson's slicing technique. After examination the sections were not preserved.
2) The remaining fetuses were placed non individually in a solution of potassium hydroxide for clearing and were stained with alizarin red (Shandon Varistain 24-T). The skeletons were examined and preserved in plastic containers. All abnormalities were recorded. - Statistics:
- The following statistical methods were used:
If the variables could be assumed to follow a normal distribution, the Dunnett-Test, based on a pooled variance, was applied for the comparison between the treated groups and the control group, otherwise the Steel-Test was applied.
Fisher's Exact test for 2x2 tables was applied if the variables could be dichotomized without loss of information (Bonferroni-Holm-corrected). - Historical control data:
- Findings both on the individual foetus and on the litter basis did not differ from the available historical control obtained in six developmental toxicity studies on the same species.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight profiles of the pregnant females were essentially similar in all groups. Mean corrected body weight gain of the treatment groups compared favourably with the control values.
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
The dams tolerated the applied dose levels of up to 1000 mg/kg bw/day without lethality and clinical signs of systemic toxicity.
Maternal body weight gain was not affected by the treatment.
Mortality:
No death occurred in the dams of group 1 (vehicle control) and in the test groups 2 - 4.
Signs and/or symptoms:
No compound-related symptoms were observed in all treatment groups. In one female (group 3) was noted a skin incrustion on the back and another female (group 1) was severely aggressive by handling.
Body weight gains and corrected body weight:
Body weight profiles of the pregnant females were essentially similar in all groups. Mean corrected body weight gain of the treatment groups compared favourably with the control values.
Reproduction data:
No compound-related differences were noted between the mean reproduction data of the test groups in comparison to the control group. In the group 2 and 4 the post-implantation loss and total embryonic deaths were significantly decreased. These findings were considered to be incidental because of the high control values. Furthermore the number of total fetuses was increased in the group 2 and 4, which is also incidental because there was no dose-relationship.
Necropsy findings:
No macroscopic changes were noted in the dams of the groups 1 - 4. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Apart from dose group 1000 mg/kg bw/day (one dead foetus) all females had viable foetuses. Pre- and postimplantation loss and mean numbers of resorption were unaffected by treatment. All parameters were comparable with the animals of the control group. Skeletal and visceral investigations detected no treatment-related malformations.
Body weight:
The weights of live fetuses exibited no significant differences on a litter and individual basis e.g. mean weight between the control group and the treatment groups.
Placenta and uterus weight:
The weights of placentae and the whole uterus showed no significant differences between the control group and the treatment groups.
Sex ratios:
The sex ratio of the fetuses was not effected by the treatment with the test substance.
External examinations:
No substance-related macroscopical findings were noted at external examination of fetuses which were considered to be an effect of the treatment with the test article. In the group 1 was noted a beginning hydrops and in the group 4 one fetus with paleness and one dead fetus.
Visceral examination:
The findings were as follows:
Group 1: 127 examined fetuses
28 hydronephrosis
9 ureter dilatation
5 ureter waved
1 runt, brain lateral sinus dilatation, other organs normal
1 thorax - blood coagulum [artifact]
1 adrenal central pinhead cyst [suspicious]
1 umbilical region - gut protrusion [artifact]
Group 2: 138 examined fetuses
34 hydronephrosis
12 ureter dilatation
3 ureter waved
1 runt, hydrocephalus internus
Group 3: 138 examined fetuses
26 hydronephrosis
5 ureter dilatation
6 ureter waved
1 ear region subcutaneous hematoma
1 umbilical region - gut protrusion [artifact]
Group 4: 140 examined fetuses
24 hydronephrosis
10 ureter dilatation
8 ureter waved
1 inguinal hernia, protrusion of gut and testis between peritoneum and trunk, muscles [artifact]
1 runt, brain lateral sinus dilatation, other organs normal
The visceral examination of the preserved fetuses did not reveal any treatment-related abnormalities.
Skeletal examination of fetuses:
Retardations:
Group 1: 141 examined fetuses
Group 2: 152 examined fetuses
single sternebrae non ossified,
significant increase at level 1% (34 fetuses out of 22 dams)
Group 3: 150 examined fetuses: no significant findings
Group 4: 152 examined fetuses
single sternebrae non ossified,
significant increase at level 5 % (29 fetuses out of 22 dams)
two sternebrae non ossified,
significant increase at level 1 % (21 fetuses out of 22 dams)
The statistically significant differences were considered to be incidental because these retardation effects were not accompanied by weight retardation of the treatment groups. The incidental character of these retardations is emphasized by the fact the values were within the normal range of variation for this strain.
Variations (examined fetuses):
Group 1: no variations
Group 2: no variations
Group 3: no variations
Group 4: no variations
Malformations (examined fetuses):
Group 1: 1 fetus beginning hydrops
Group 2: no findings
Group 3: no findings
Group 4: no findings
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: embryotoxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: teratogenicity
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- Fatty acids, C16-18, 2-ethylhexyl esters up to a dose of 1000 mg/kg bw/day does not produce any embryo- and foetotoxic or teratogenic effects. The NOAEL for maternal-, developmental-, embryo-, foetotoxicity and teratogenicity is deduced ≥ 1000 mg/kg bw/day.
Referenceopen allclose all
Table 1: Body weights
Dose group |
Control |
100 mg/kg bw/day |
300 mg/kg bw/day |
1000 mg/kg bw/day |
Gestation day 0 |
212.3 |
202.6 |
219.7 |
209.0 |
Gestation day 6 |
263.1 |
255.5 |
273.5 |
259.4 |
Gestation day 16 |
340.7 |
338.6 |
361.7* |
341.5 |
Gestation day 20 |
403.3 |
400.7 |
428.0* |
407.9 |
*Dunnett-Test based on pooled variance, p < 0.05
Table 2: Summary of mating performance of the females
Dose group
|
Control |
100 mg/kg bw/day |
300 mg/kg bw/day |
1000 mg/kg bw/day |
No. of mated females |
24 |
23 |
23 |
24 |
No. of pregnant females* |
23 |
22 |
23 |
24 |
No. of premature litters** |
0 |
0 |
0 |
0 |
No. of mortalities |
0 |
0 |
0 |
0 |
*Included in the statistical analysis
**Premature litter is an event in the cage immediately before the caesarean section
Table 3: Reproduction parameters for dams with live foetuses
Dose group
|
Control |
100 mg/kg bw/day |
300 mg/kg bw/day |
1000 mg/kg bw/day |
Number of dams |
23 |
22 |
23 |
24 |
Corpora lutea (total) |
376 |
343 |
403 |
390 |
Corpora lutea (mean±SD) |
16.3±1.5 |
15.6±1.2 |
17.5±1.6 |
16.2±2.3 |
Implantation sites (total) |
316 |
301 |
367 |
346 |
Implantation sitesaas: -% of corp. lutea - mean±SD |
84.0 13.7±3.7 |
87.8 13.7±2.5 |
91.1 16.0±1.9 |
88.7 14.4±3.1 |
Pre-implantation loss (total)b |
60 |
42 |
36* |
44 |
Pre-Implantation lossas % of corpora lutea |
16.0 |
12.2 |
8.9 |
11.3 |
Post-implantation lossb |
11 |
24 |
20 |
12 |
Post-implantation loss as % of implantation sites |
3.5 |
8.0 |
5.4 |
3.5 |
Embryonic deaths totalb |
11 |
24 |
20 |
12 |
Embryonic resorptions (total)a |
9 |
18 |
20 |
10 |
Embryonic resorptions as % of implantation sites (mean±SD) |
2.8±0.4 |
6.0±0.8 |
5.4±0.9 |
2.9±0.4 |
Foetal resorptions (total)a |
2 |
6 |
0 |
2 |
Foetal resorptionsas % of implantation sites(mean±SD) |
0.6±0.1 |
2.0±0.3 |
0 |
0.6±0.1 |
Fetuses per dam (mean±SD) |
13.3±3.6 |
12.6±3.1 |
15.1±2.4 |
13.9±2.7 |
Live foetusesa |
305 |
277 |
347 |
334 |
Dead foetusesa |
0 |
0 |
0 |
0 |
Malformed foetuses |
0 |
0 |
0 |
0 |
Uterus weightc(mean±SD) |
81.3±24.1 |
77.4±18.0 |
97.0±15.7* |
88.8±18.3 |
aSteel Test
bFishers Exact Test (Bonferroni-Holm-Corrected)
cDunnett-Test based on pooled variance
*p < 0.05
Table 4: Developmental parameters for offspring
Dose group
|
Control |
100 mg/kg bw/day |
300 mg/kg bw/day |
1000 mg/kg bw/day |
Number of live foetuses (m/f) |
305 (154/151) |
277 (141/136) |
347 (162/185) |
334 (165/169) |
Sex ratio (m/f) |
0.51/0.49 |
0.51/0.49 |
0.47/0.53 |
0.49/0.51 |
Weights of live foetuses (mean±SD) |
4.1±0.8 |
4.1±0.6 |
4.4±0.8 |
4.2±0.6 |
No. of runts |
1 |
2 |
1 |
2 |
Table 5: results of skeletal examination of offspring
Dose group
|
Control |
100 mg/kg bw/day |
300 mg/kg bw/day |
1000 mg/kg bw/day |
No abnormal findings, number (% of total) |
10 (6.3%) |
12 (8.3%) |
32 (18.0%)** |
10 (5.8%) |
6 ossified sternebrae, number (% of total) |
124 (78.0%) |
120 (83.3%) |
151 (84.8%) |
153 (89%)** |
** Fishers Exact Test (two-sided), p < 0.01
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises two adequate and reliable studies (Klimisch score 2) from reference substances with similar structures and intrinsic properties. Read-across is justified based on common precursors and breakdown products of hydrolysis and consistent trends in environmental fate, ecotoxicological and toxicological profile (refer to the endpoint discussion for further details). The selected studies are thus sufficient to fulfil the standard information requirements set out in Annex VIII-IX, 8.7, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for read-across
Data on developmental toxicity of Fatty acids C8-10, C8-10 alkyl esters are not available. The assessment was therefore based on studies conducted with analogue substances as part of a read-across approach, which is in accordance with Regulation (EC) No. 1907/2006, Annex XI, 1.5. For each specific endpoint the source substance(s) structurally closest to the target substance is/are chosen for read-across, with due regard to the requirements of adequacy and reliability of the available data. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the analogue read-across approach is provided in the technical dossier (see IUCLID Section 13).
Developmental toxicity/teratogenicity
CAS 111937-03-2
The potential of isononanoic acid, C16-18 alkyl esters (CAS 111937-03-2) to cause developmental toxicity was assessed in a study performed using a study protocol similar to OECD guideline 414 (WoE, 1997). 23-24 pregnant female Sprague-Dawley rats/dose level were administered 0, 100, 300 and 1000 mg/kg bw/day of the test substance by gavage on gestation Day 6 to 15.
No signs of systemic toxicity were observed in the P-females and no treatment-related effects were observed. One female in the high-dose group had blood in the uterine horn, but this is not considered to be treatment-related as no related effects were observed. One female in each of the control group and the low-dose group did not become pregnant, while all the pregnant females had viable foetuses. No treatment-related effects on the reproductive parameters (number of corpora lutea, implantation sites, pre-implantation loss, post-implantation loss, embryonic deaths, embryonic resorptions, foetal resorptions, live foetuses, dead foetuses) were observed.
The external examination of the F1-foetuses did not reveal any treatment-related macroscopic findings. The skeletal examination showed a statistically significant increase in the number of foetuses with 6 ossified sternebrae in the mid-dose group (300 mg/kg bw/day). As there were no increases in ossification anywhere else and no overall increase in abnormal findings for this group, the result is considered to be incidental. The results for the remaining offspring parameters (body weight, placental weight, sex ratio) were comparable between the control and treatment groups.
The NOAEL developmental is considered to be ≥ 1000 mg/kg bw/day.
The most recent version of OECD guideline 414, adopted in January 2001, stipulates that the dams should be dosed from implantation (gestation Day 0) to the day prior to scheduled caesarean section (around gestation day 19 for rats). The study was performed according to the previous version of OECD guideline 414, adopted in May 1981, which recommended exposure during organogenesis; gestation Day 6-15 for rats. The available data on repeated dose toxicity and developmental toxicity is of high quality and does not show treatment-related adverse effects at dose levels up to and including the highest dose of 1000 mg/kg bw/day, indicating that adverse effects are unlikely to occur in the period prior to Day 6 of gestation. Based on the available data it is not considered necessary to perform an additional, dedicated, developmental toxicity study.
CAS 91031-48-0
A developmental toxicity study was performed according to OECD Guideline 414 under GLP conditions (WoE, 1994). Twenty-four female Sprague-Dawley rats per dose were administered 0, 100, 300 and 1000 mg/kg bw/day Fatty acids, C16-18, 2-ethylhexyl esters (CAS 91031-48-0) once daily from day 6 up to day 15 of gestation via gavage in arachidis oil as vehicle. Maternal animals were examined for clinical signs, mortality, body weight changes, and gross pathology. Number of abortions, pre- and post-implantation losses, total litter losses, duration of pregnancy, early and late resorptions, dead foetuses, pregnancy rate, placenta and uterus weight were assessed. In foetuses body weight changes, number of live offspring, sex ratio, external, visceral and skeletal malformations were assessed.
No adverse effects on maternal toxicity, maternal developmental toxicity and foetuses were observable up to the limit dose of 1000 mg/kg/day.
Based on the absence of adverse toxic effects, the NOAEL for developmental toxicity/teratogenicity and for maternal developmental toxicity is considered to be 1000 mg/kg bw/day.
CAS 22393-85-7
A combined repeated dose toxicity and reproduction/developmental toxicity screening study was performed according to OECD Guideline 422 under GLP conditions (Rossiello, 2014). 10 rats/ sex/dose were administered 0, 100, 300 and 1000 mg/kg bw/day Tetradecyl oleate (CAS 22393-85-7) once daily, via gavage. Males were exposed for 28-29 days, from two weeks before mating on test day one until after mating. Females were exposed for 54 days (during 2 weeks prior to mating, during mating, during post-coitum, and during 3 days of lactation).
The results of the offspring (viability) parameters pre-implantation loss, pre-birth loss, stillbirths, live births, cumulative pup loss on day 4 post-partum, litter size and pup weight were comparable between control and treatment group. Clinical signs of pups such as pallor, cold to touch, small and/or bruised muzzle, were observed in control and treatment groups and were therefore not considered to be of toxicological relevance. The number of male pups was significantly increased compared with the control group on Day 4 only. As the sex ratio (absolute percentage of males to females) was not significantly different from control, this is not considered to be a toxicologically relevant effect. The gross pathological examinations did not reveal any treatment-related effects. Based on the lack of effects, the NOAEL for developmental toxicity/teratogenicity is considered to be ≥ 1000 mg/kg bw/day.
Overall conclusion for developmental toxicity/teratogenicity
The potential for developmental toxicity and teratogenicity of the source substance (Tetradecyl oleate, CAS 22393-85-7) was assessed in a reproductive/developmental screening study (OECD 422). Further, isononanoic acid, C16-18 alkyl esters (CAS 111937-03-2) and Fatty acids, C16-18, 2-ethylhexyl esters (CAS 91031-48-0) were tested for developmental toxicity according to OECD 414. In all studies, NOAEL values for developmental toxicity/teratogenicity were at the currently applied limit dose value of 1000 mg/kg bw/day. Therefore, no hazard to reproduction was identified. Based on the available data and following the analogue approach, the target substance Fatty acids C8 -10, C8 -10 alkyl esters is considered to be not toxic to development.
Justification for classification or non-classification
According to Article 13 of Regulation (EC) No. 1907/2006 "General Requirements for Generation of Information on Intrinsic Properties of substances", information on intrinsic properties of substances may be generated by means other than tests e.g. from information from structurally related substances (grouping or read-across), provided that conditions set out in Annex XI are met. Annex XI, "General rules for adaptation of this standard testing regime set out in Annexes VII to X” states that “substances whose physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity may be considered as a group, or ‘category’ of substances. This avoids the need to test every substance for every endpoint". Since the analogue concept is applied to Fatty acids C8-10, C8-10 alkyl esters (CAS 129677-93-6), data will be generated from data for reference source substance(s) to avoid unnecessary animal testing. Additionally, once the analogue read-across concept is applied, substances will be classified and labelled on this basis. Based on the analogue read-across approach, the available data on toxicity to reproduction does not meet the classification criteria according to Regulation (EC) 1272/2008, and is therefore conclusive but not sufficient for classification.
An OECD Guideline 422 study will not provide evidence for definite claims of no reproduction/developmental effects. However, since no adverse effects on reproduction and development was noted up to and including the limit dose of 1000 mg/kg bw/day in all available studies (including the two developmental toxicity studies), the conclusion of no classification (conclusive but not sufficient for classification) is considered to be justified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.